La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Affect in Parkinson's disease: validation of the two-factor approach.

Identifieur interne : 001A94 ( Main/Exploration ); précédent : 001A93; suivant : 001A95

Affect in Parkinson's disease: validation of the two-factor approach.

Auteurs : Emmanuelle Pourcher [Canada] ; Sophie Rémillard ; Henri Cohen

Source :

RBID : pubmed:19747694

English descriptors

Abstract

Depression in Idiopathic Parkinson's disease (IPD) is frequent, difficult to recognize, under managed and has a profound impact on quality of life. Current categorization of diagnosis in psychiatry poorly applies to the protean manifestations of mood disorders presented by parkinsonian patients. In this study we have chosen to dissect the state of depressive mood as assessed with the Beck Depression Inventory (BDI) at different points in time of pharmacological interventions using a dimensional approach. The 21 items of the BDI were classified in two new categories or factors: hyperkinetic and hypokinetic. The hyperkinetic factor included all items related to unbalanced intrusions of negative feelings and ideas, as well as to behavioral hyperactivity. The hypokinetic factor included all items related to loss of drive for appetitive behaviors and loss of mental and physical energy. The objectives were to (1) compare different pharmacological treatments on the two-factor approach in PD depression, (2) determine the influence of levodopa therapy on the two-factor approach, and (3) explore the two-factor approach in placebo conditions. Three sets of analyses using the hypo/hyperkinetic dichotomy favour a neurobiological dissociation of these factors in response to pharmacological intervention: symptoms of the hyperkinetic factor are responsive to serotonergic drugs while those of the hypokinetic one are not and may even show deterioration under SSRIs. In contrast, the hypokinetic factor is responsive to dopaminergic drugs and may show deterioration under serotonergic drugs. Furthermore, the two factors seem to transiently dissociate on placebo intervention aiming at correcting either mood or motor status. The dimensional approach to depression symptomatology may thus be of heuristic value in probing aminergic modulation of mood in IPD and establishing new correlations between affective and motor symptoms.

DOI: 10.1016/j.jns.2009.08.048
PubMed: 19747694


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Affect in Parkinson's disease: validation of the two-factor approach.</title>
<author>
<name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name>
<affiliation wicri:level="1">
<nlm:affiliation>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte-Anne, Québec, Canada. psa@riq.qc.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte-Anne, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Remillard, Sophie" sort="Remillard, Sophie" uniqKey="Remillard S" first="Sophie" last="Rémillard">Sophie Rémillard</name>
</author>
<author>
<name sortKey="Cohen, Henri" sort="Cohen, Henri" uniqKey="Cohen H" first="Henri" last="Cohen">Henri Cohen</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:19747694</idno>
<idno type="pmid">19747694</idno>
<idno type="doi">10.1016/j.jns.2009.08.048</idno>
<idno type="wicri:Area/PubMed/Corpus">000D76</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D76</idno>
<idno type="wicri:Area/PubMed/Curation">000D76</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D76</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000D76</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000D76</idno>
<idno type="wicri:Area/Ncbi/Merge">000B45</idno>
<idno type="wicri:Area/Ncbi/Curation">000B45</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000B45</idno>
<idno type="wicri:Area/Main/Merge">001C07</idno>
<idno type="wicri:Area/Main/Curation">001A94</idno>
<idno type="wicri:Area/Main/Exploration">001A94</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Affect in Parkinson's disease: validation of the two-factor approach.</title>
<author>
<name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name>
<affiliation wicri:level="1">
<nlm:affiliation>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte-Anne, Québec, Canada. psa@riq.qc.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte-Anne, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Remillard, Sophie" sort="Remillard, Sophie" uniqKey="Remillard S" first="Sophie" last="Rémillard">Sophie Rémillard</name>
</author>
<author>
<name sortKey="Cohen, Henri" sort="Cohen, Henri" uniqKey="Cohen H" first="Henri" last="Cohen">Henri Cohen</name>
</author>
</analytic>
<series>
<title level="j">Journal of the neurological sciences</title>
<idno type="eISSN">1878-5883</idno>
<imprint>
<date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Aged</term>
<term>Antidepressive Agents (therapeutic use)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Depression (diagnosis)</term>
<term>Depression (drug therapy)</term>
<term>Depression (etiology)</term>
<term>Dopamine (metabolism)</term>
<term>Female</term>
<term>Humans</term>
<term>Hyperkinesis (chemically induced)</term>
<term>Hypokinesia (chemically induced)</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Psychiatric Status Rating Scales</term>
<term>Reproducibility of Results</term>
<term>Serotonin (metabolism)</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Dopamine</term>
<term>Serotonin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antidepressive Agents</term>
<term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en">
<term>Hyperkinesis</term>
<term>Hypokinesia</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en">
<term>Depression</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Depression</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Depression</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Psychiatric Status Rating Scales</term>
<term>Reproducibility of Results</term>
<term>Time Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Depression in Idiopathic Parkinson's disease (IPD) is frequent, difficult to recognize, under managed and has a profound impact on quality of life. Current categorization of diagnosis in psychiatry poorly applies to the protean manifestations of mood disorders presented by parkinsonian patients. In this study we have chosen to dissect the state of depressive mood as assessed with the Beck Depression Inventory (BDI) at different points in time of pharmacological interventions using a dimensional approach. The 21 items of the BDI were classified in two new categories or factors: hyperkinetic and hypokinetic. The hyperkinetic factor included all items related to unbalanced intrusions of negative feelings and ideas, as well as to behavioral hyperactivity. The hypokinetic factor included all items related to loss of drive for appetitive behaviors and loss of mental and physical energy. The objectives were to (1) compare different pharmacological treatments on the two-factor approach in PD depression, (2) determine the influence of levodopa therapy on the two-factor approach, and (3) explore the two-factor approach in placebo conditions. Three sets of analyses using the hypo/hyperkinetic dichotomy favour a neurobiological dissociation of these factors in response to pharmacological intervention: symptoms of the hyperkinetic factor are responsive to serotonergic drugs while those of the hypokinetic one are not and may even show deterioration under SSRIs. In contrast, the hypokinetic factor is responsive to dopaminergic drugs and may show deterioration under serotonergic drugs. Furthermore, the two factors seem to transiently dissociate on placebo intervention aiming at correcting either mood or motor status. The dimensional approach to depression symptomatology may thus be of heuristic value in probing aminergic modulation of mood in IPD and establishing new correlations between affective and motor symptoms.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Cohen, Henri" sort="Cohen, Henri" uniqKey="Cohen H" first="Henri" last="Cohen">Henri Cohen</name>
<name sortKey="Remillard, Sophie" sort="Remillard, Sophie" uniqKey="Remillard S" first="Sophie" last="Rémillard">Sophie Rémillard</name>
</noCountry>
<country name="Canada">
<noRegion>
<name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A94 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A94 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:19747694
   |texte=   Affect in Parkinson's disease: validation of the two-factor approach.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:19747694" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022